285139-46-0Relevant academic research and scientific papers
Discovery of a potent, orally bioavailable pyrimidine VLA-4 antagonist effective in a sheep asthma model
Semko, Christopher M.,Chen, Linda,Dressen, Darren B.,Dreyer, Mark L.,Dunn, Whitney,Farouz, Francine S.,Freedman, Stephen B.,Holsztynska, Elizabeth J.,Jefferies, Michael,Konradi, Andrei W.,Liao, Anna,Lugar, Judevin,Mutter, Linda,Pleiss, Michael A.,Quinn, Kevin P.,Thompson, Thomas,Thorsett, Eugene D.,Vandevert, Christopher,Xu, Ying-Zi,Yednock, Ted A.
, p. 1741 - 1743 (2011/05/04)
A series of N-(pyrimidin-4-yl)-phenylalanine VLA-4 antagonists is described. Optimization of substituents at the 2 and 5 positions of the pyrimidine ring gave 14, a very potent VLA-4 inhibitor which is orally active in a sheep asthma model.
STEROID SPARING AGENTS AND METHODS OF USING SAME
-
Page/Page column 558, (2010/02/14)
This invention relates generally to the use of a steroid sparing agent for the preparation of a medicament for the treatment of inflammatory bowel diseases (IBD), asthma, multiple sclerosis (MS), rheumatoid arthritis (RA), graft versus host disease (GVHD), host versus graft disease, and various spondyloarthropathies, comprising administering a steroid sparing immunoglobulin or small molecule composition to a patient in need thereof. The invention also relates generally to combination therapies for the treatment of these conditions.
